SNDL

the_mammynun

With SNDL It's important to understand that they've acquired every business/asset that defines them. They have some decent retail assets (ValueBuds, SpiritLeaf), but they've only achieved that through agressive dilution and M&A. In my view they've never proven they can grow organically. I also feel they are weighed down by poor/non-strategic acquisitions in alcohol retail, grow ops (Valens), and complicated US structure (Sunstream) which have not proven advantageous.  Overall I'm not impressed with their management or diversification strategy, but they have lots of cash and a #2 position in Canadian retail. 

Ausdummer

SNDL earnings in 8 days.

MrSquigglyPub3s

Took a big loan from the bank Friday to go all in on WeBull and SNDL!!!!! My the tardnation god bless me with tardness!!!!!

Ausdummer

[https://www.canadianinsider.com/company-insider-filings?ticker=SNDL](https://www.canadianinsider.com/company-insider-filings?ticker=SNDL)

Ausdummer

SNDL with 1.25M shares repurchased in Jan. One of the few approved buybacks being actioned on in this space

Background-Summer-56

Translation: SNDL issued us convertible notes and we need you to buy the shares that we just converted. We'll, my bosses did anyway, and I want them to keep hiring me to post this slop.

Gambelero

Geo is right of course. Dilution is not the primary cause of CGC’s stock price resiliency. SNDL is worth a lot more now because they diluted whole hog at the top of their meme run. VFF was very smart to dilute at the end of the Texas hemp run-up.

Total_Schedule591

I have 1 share of SNDL that made 2cents today, my top performer

The_Insider_Edge

Could see both of these get bought out by $SNDL, $CGC or $TLRY very soon. M&A accumulation has begun for cannabis and schedule III is suppose to happen this week before month end!

constructiontimeagnn

$FCX , if the Golden Egg is precious, the Goose that lays them is...... $FCX mines Gold, Silver and most precious of all Copper. Structural Deficit, even if they open up the mines, even if they start using Aluminum more than Copper, $FCX continues to climb, more so when mine Grasberg mine reopens. Long on $SNDL on Rescheduling Pending, $BB on QNX imbeddedness in all things mechanized, autonomous, humanoids. Long on $UAMY only antimony full vertical in the US, $EU only full vertical Uranium extraction vs pit mining, and can yellowcake their own Uranium.

FiduciaryArchitect

Excellent analysis OP! SNDL is totally undervalued in the current market. I believe this will be a transformative year with rescheduling, FCF growth and recent acquisitions like 1CM coming to fruition.

Twist_of_Fate_44

Yours is one of the weakest pump attempts I've seen on this board in sometime now Without looking, I'm gonna guess that you're 'invested' in Auxly .. but maybe have some SNDL, TLRY or HITI too??

Kbarbs4421

I call bullshit on that. Hile true in theory, its not true in practice. I've had accounts with Schwab for more than a decade now. Not once have any of the equities I hold been subject to such restrictions, and I've held some real sketchy shit at certain points. And these are some of the strongest companies in the sector with respect to balance sheets, reporting compliance, leadership, institutional investment, etc. CRON, VFF, SNDL. Meanwhile the underwater sketchy ass companies are still good. I get your point, but it's a bit disingenuous.

bourbonwarrior

Not a conspiracy, I have to call into Schwab to buy VFF and SNDL. Once purchased, I can direct the sell, but I am unable to secure shares without a broker, they are viewed as "restricted". This started, for me, about 10 trading days ago.

the_mammynun

Well maybe in the case of SNDL

Kbarbs4421

That's what makes so little sense. The equities reportedly subject to this restriction (SNDL, VFF, and HITI) are among the lowest risk in the cannabis sector. Strange.

bourbonwarrior

Restricted, but SNDL has 240.6M in cash, no debt. Not high risk, not a pump/dump either. No reason why other than they were "flagged internally as high risk."

bourbonwarrior

Yep, SNDL, VFF for example. Started about 10 trading days ago for me

Kbarbs4421

Just tried SNDL. Couldn't place it online. Error message says: "Opening transactions for this security must be placed with a broker. Contact us." Bullshit.

Love2Garden860

SNDL

benderok37

Why would people invest into $CGC or $TLRY if there is better players? Such as $HITI, OGI, ACB, SNDL? I am sure some people will say that ACB also not that good, but if you look at their last 2 year perfomance, you will see they did a good progress. Cleaned balance sheet, debt free, 3% or so dillution, growing medical cannabis etc. 

UsedState7381

I'm not sure if the mods allows it here since it's the NY Post, but basically it talks about banks looking at MSOs again now that Trump signed the EO to get the DOJ to reclassify cannabis. But, some of them like, JP Morgan, don't want to move until the Schedule 3 is in effect and the law changes. Curiously, JP Morgan owns a little stake on SNDL and SNDL has plans to expand operations in the USA(they're currently down on their position).

Forest_City_Frolfer

That's good to know. Thanks for the correction Weirdly Canopy Growth owned Tokyo Smoke (Hiku Brands) and TWEED for years with numerous stores across a number of provinces. They must've had some sort of corporate structure to get around the rules. SNDL also currently has a ton of retail locations as well, a bunch in Ontario too.

Russticale

Feels like the old days where US cannabis reform is sooner than ever and TLRY is getting hyphe from earnings to jump start the up trend. $1.50 Calls expiring today on CGC might print.  I snagged that hoping for the sympathy play.  Also added some april/june calls for HITI, and SNDL.  Liquidity hits the listed canadian stocks first, so hoping to ride that wave and roll profit back into US names.  Hoping today sparks the uptrend.  Stocks looking ready, nice to see some structure after a 5 year sled ride.

Remarkable_Garage727

This is why I think SNDL will outperform TLRY, SNDL is buying back its stock while TLRY keeps diluting

GeoLogic23

Parallel is with SNDL and Fluent is an investment of Miracle Gro (option to reacquire).

TheOriginalBushToad

Can we just legalize dope already. These TLRY and SNDL bags I've been carrying for years are killing my buzz....

No_Cell6708

Rolling vs annual is irrelevant. You can clearly see the long-term trend is a decline. No, they didn't suddenly reverse this. They have a history of sugarcoating their numbers through acquisitions, not through actual, organic growth. You keep bragging about top-line as though it's all that matters(it doesn't), but doesn't SNDL beat them there anyway? TLRY press release says: "Maintaining the number one position in revenue" This would imply they had been leading before last earnings, but looking at the numbers this doesn't seem to be the case. It looks like SNDL has $244m compared to the $206 or whatever from TLRY. They also seem to have lost to SNDL in the previous quarter. What am I missing here? I'm going to ignore the fact that you keep giving pre-excise revenue stats too lol Again, I'm not saying that they won't have a solid q2. I'm saying there are better investments out there imo.

Parking-Energy2875

Dude bought 1.1k shares of SNDL at its peak 13 years ago he’s in pain still

Ausdummer

SNDL leading the LP way

Trayeboujee

SNDL has something cooking behind the curtains, there are many hidden gems and secrets that will be revealed in the new year

Love2Garden860

FUCK YEAH 2026!!!! SNDL to the moon 🚀😝

Swollenpajamas

Thanks for making me feel better about my SNDL bought at $30+ that I’m still holding. Haha.

the_mammynun

High Tide has never used bridge financing to buy distressed assets in the US. You are referring to SNDL's "Sunstream". We're going to have to agree to disagree regarding Nasdaq. Raj has spoken several times about the fact that he could enter the US market today if Nasdaq released language permitting it. There's nothing illegal about running a cannabis company in legal rec state while abiding by state regulations. It simply introduces risks to investors that Nasdaq doesn't want to be accountable for. Canopy USA was created in the way it was because CGC didn't want to forfeit their NYSE listing, not because of federal law.

benderok37

All Canadian companies red (CGC, ACB, HITI, OGI, TLRY, SNDL) yet, American MSOS green, big green...  Any explanation? 

benderok37

Looking at Canadian weed stocks, which one would be good bet? ACB, CGC, SNDL, TLRY?  Any bulls there can explain?  From valuation standpoint acb look very attractive, but many people call em scam 

Optimal-Report-1000

What are the more credible cannabis holders?? From what I can tell SNDL has completely alter their business dynamic since they hyped out after IPO. They should be market cap with other liquor distributors, not just cannabis compared

crunchsoop

This guy has been a long term SNDL holder. I can tell. One day, friend. One day.

onEstusFlask

SNDL

Love2Garden860

So do you mean, a “sell the news” type of scenario. Because that’s the reality of the sector. Investors, (the real players) are taking profits and us little guys get stuck holding the bags, again. 🤷🏼 HITI & SNDL are both good companies with solid fundamentals, our day will come! Even if it’s taking longer than we hoped

the_mammynun

Yes HITI investors think that because for years the stock was sold off significantly every single time we posted a record quarter. It's as if someone was trying to suppress any positive momentum in the stock. Hopefully in the future SNDL will not "play games" with our stock and will stick to regular "for-profit" investing / trading. 

Love2Garden860

That seems to be a common claim with HITI investors, but maybe SNDL is just looking to free up some cash for their own operations or acquisitions. Profit taking is something we all try to do. So when a competitor sees an opportunity and takes advantage, it doesn’t make them the bad guy. When HITI stock dips down it doesn’t mean there’s manipulation. When you have large institutional investors accumulating SNDL in the most recent quarters, like Morgan Stanley, JP, Morgan, Citadel, and others it just confirms that they are making the right moves.

Russticale

Ready to be absolutely smoked again.  But going long here and going to be trading less.  2 year old plus another comin in Feb, gotta focus on what matters.   Calls for HITI, SNDL in april 2026.  Shares of MariMed, a little MSOX. Ill check in on the boys from time to time.

the_mammynun

SNDL trades HITI to sabotage share price movements. They owned up to 10% recently but now it's closer to 4%. Have fun with that exposure.

Trayeboujee

Quick fact checks and things worth reconsidering: 1) Valens isn’t just a “talked about” asset — it’s already integrated and creating real synergies. SNDL completed the Valens acquisition in early 2023, bringing in extraction, processing, and manufacturing capabilities that materially expanded product offerings and lowered cost structures. The combined company generates over $1 B in pro-forma revenue and SNDL has realized annualized cost savings that have already exceeded targets. 2) They’re not sitting on GMP hopes ,they are executing partnerships. SNDL has signed agreements with HYTN for EU-GMP-certified manufacturing and received initial purchase orders under that partnership. HYTN will process EU GMP product for export to regulated markets like the UK, showing SNDL is moving toward standardized pharmaceutical production capacity, not just implying it. HYTN Innovations Inc. 3) They do have a strategic balance sheet , no debt & large cash/investments. As of early 2025, SNDL reported hundreds of millions in cash and marketable securities, zero debt, and ~$1.1 B in net book value. That gives them flexibility to deploy capital, buy back stock, and pursue growth or restructuring opportunities. 4) The U.S. optionality you dismiss isn’t zero , it’s structured differently. SNDL’s SunStream vehicle holds secured positions in U.S. cannabis operators that can convert into equity if federal law changes (e.g., Schedule III rescheduling, which would unlock banking and tax efficiencies). If that catalyst hits, those positions instantly become operating assets with real revenue potential. This is a legally embedded upside, not just narrative fluff. 5) They’re strategically pruning and optimizing operations, not just holding failing assets. SNDL has rationalized its facility footprint, cut costs, improved margins, and is expanding higher-growth segments (e.g., infused products, retail data monetization). These are execution moves toward profitability, not just high-level promises. Yes, SNDL has legacy challenges and the transition isn’t complete ,but facts show they’re actively executing acquisitions, reducing costs, improving cash flow, building GMP partnerships, and holding structured optionality in the U.S.. That’s a lot more than “vague words on a slide.” If you’re bearish because you think nothing is happening behind the scenes, the actual filings and press releases suggest there are operational and strategic catalysts worth examining

Love2Garden860

The claim of zero organic expansion is factually incorrect; in 2024 and 2025, SNDL reported consistent same store sales growth in its cannabis retail segment and double digit revenue increases in its high margin private label liquor brands. The strategic acquisition of Valens and the restructuring of Parallel through the SunStream USA platform were not simple dilutive purchases but sophisticated credit to equity conversions that "cleansed" these assets of the very debt you criticize, leaving SNDL with a solid balance sheet of over $240 million in unrestricted cash and zero debt. Finally, the comparison to High Tide is ironic, as you know SNDL is a significant shareholder in High Tide, and unlike pure play retailers, SNDL possesses a $500 million plus annual revenue stream from its liquor segment that provides a financial stability and safety net that few in the industry can match. I agree High Tide is a good company! That’s exactly why SNDL bought millions of shares of it. We’re very glad to have them working for us.

the_mammynun

Please stop pumping garbage. We're already stuck with other meme stocks like TLRY and CGC.  Take a look at HITI if SNDL attracts you. They have a lot of similar assets but better management and financials.  HITI = Smart, organic growth SNDL = Thoughtless dilution-driven M&A with lots of cash.

Orennji

There is no tangible evidence any of those alleged future cash flows will meaningfully change SNDL's financial position. The very small steps they've taken towards any of those goals have not been promising at all. \>However, SNDL has explicitly stated it is shifting capital allocation away from asset-heavy retail and cultivation toward: services manufacturing structured credit pharma-grade channels The closest thing they have to being a "service" provider might be the acquisition of Valens. But the Valens "toll processor" business model fell apart years ago because, predictably, the LPs just bought their own extraction equipment and cut out the middleman. Besides that, SNDL holds no unique patents, no significant investment in R&D for new cultivars or products, no particularly popular brands/IPs. In other words, none of the things an asset-light business should have. Structured credit is just a fancy way of saying money lending. Which other financial institutions already do for Cannabis companies. SNDL's liquid capital pool of a few hundred million is nothing compared to the scale of legitimate banks once they get in the game. \>SNDL already has access to GMP via HYTN and MediPharm So the idea is that a pharma company will pay SNDL to pass the work onto those companies? Why deal with SNDL at all then? What do they even add? \> SNDL’s thesis is standardized, modular, redeployable capacity, not fixed mega-facilities. They still need to be GMP-certified, which they're currently not. But let's pretend they will be in the next 6-12 months. Then what? What are they going to manufacture for pharma? The only Cannabis plant-derived product with an FDA-approved indication is Epidiolex, which Jazz manufactures in-house with their own GMP-cert facility. As far as I can tell, no other plant-derived medication is on the horizon for FDA approval. Clinical trials for new drugs typically take 7-10 years before there is sufficient data for FDA approval (which is roughly how long it took for Epidiolex). Even if a large pharma company decided to begin researching a new plant-derived drug and for some reason chose SNDL as their CDMO, the pods will not be producing at scale for almost a decade. Big Pharma can also completely avoid the need for plant cultivation by designing totally synthetic Cannabinoid drug candidates. \>Private equity often looks wrong before the cycle turns. The test is not Jushi’s current revenue. It is what assets survive and who controls them post-distress. Do they explain anywhere exactly **what** these "assets" are supposed to be? More cultivation? More brick-and-mortar stores? In other words, more of the opposite of being "asset-light"? I cannot imagine they are paying for rights to the flagship Jushi brand, "Beyond Hello". The same pattern is repeated for their other investments - Skymint, Parallel, etc. All failed asset-heavy operators. But maybe the plan is to liquidate the assets and do a quick flip. Except.. the total liabilities exceed total assets to such an extent that selling off every gram in inventory and every "Beyond Hello" storefront would still not be enough to come out ahead. At this point, we need to be honest and admit SunStream was horribly conceived from the start and is completely aimless in how to move forward. If Zach George and the gang have learned anything from this, they should practice what they're preaching and actually invest in asset-light companies, like up-and-coming brands, seed-stage startups, and undervalued R&D projects. Anyway, I don't mean to come off as a basher against SNDL. I was a brief shareholder when my Inner Spirit shares were acquired, and I took all my profit and principal out immediately because I just didn't see a coherent plan from SNDL. And I still don't, no matter how "cheap" the stock has gotten.

Trayeboujee

1. “Most revenue is low-margin retail, grows, and meme rallies” This criticism is fair today — but backward looking. Evidence / facts: Yes, current revenue is still dominated by alcohol retail and legacy cannabis operations. That is exactly why SNDL trades at a depressed valuation. However, SNDL has explicitly stated it is shifting capital allocation away from asset-heavy retail and cultivation toward: services manufacturing structured credit pharma-grade channels Key point: Markets re-rate on future cash flows, not legacy revenue. The DD is not claiming current revenue quality is high. It argues the business model is changing, and the market is still pricing the old one. 2. “Others already have GMP facilities, SNDL is far behind” This is partially incorrect and partially misunderstood. Evidence: SNDL already has access to GMP via HYTN and MediPharm, which is why those names matter. GMP does not need to be owned to be monetized. In pharma, CDMOs (Contract Development & Manufacturing Organizations) routinely trade at high multiples without owning all upstream assets. Tilray and Aurora own GMP facilities, but: They are capital intensive Often underutilized Built for export flower, not scalable pharma manufacturing Key distinction: Owning a GMP building ≠ owning a GMP platform. SNDL’s thesis is standardized, modular, redeployable capacity, not fixed mega-facilities. Asset-light here does not mean “middleman.” It means capital efficiency + redeployability, which matters when demand is uncertain. 2.5. “Name one AI use that makes money today” Fair critique. There is no claim that AI is currently driving material revenue. Correct framing: AI here is a cost, compliance, and scalability enabler, not a revenue line item. Pharma manufacturing requires: batch traceability audit trails real-time quality monitoring AI and automation reduce: compliance costs batch failures labor intensity This is not speculative upside today. It is table stakes for FDA-adjacent manufacturing tomorrow. 3. “Modular grows failed before, Delta 9 proves this” This is where the critique conflates cultivation with manufacturing, and that matters. Evidence-based distinction: Delta 9 used modular systems for cultivation, which is a commodity business. The pods thesis is manufacturing, not growing. Pharma manufacturing is already modular by design (clean rooms, isolated processes, redundancy). Why this matters: Cultivation benefits from scale and sunlight. Manufacturing benefits from: isolation repeatability regulatory containment SNDL is not trying to outgrow greenhouses. They are trying to outmanufacture competitors in regulated products. 4. “SunStream investments look terrible (e.g. Jushi)” This is the strongest bear point — and also the most misunderstood. Evidence: SunStream invested into distressed operators before Schedule III clarity. Those investments were credit-first, not equity-first. Accounting forced SNDL to recognize losses before earnings. Key clarification: SunStream was never about “picking winning MSOs.” It was about: senior secured lending asset control restructuring optionality Private equity often looks wrong before the cycle turns. The test is not Jushi’s current revenue. It is what assets survive and who controls them post-distress. 5. “Why would pharma partner with SNDL?” They would not partner with SNDL today. They would partner when three things are true: Evidence-based prerequisites: GMP-certified manufacturing capacity (via HYTN / MediPharm) Regulatory-grade data, documentation, and DMF readiness Financial stability and long-term commitment SNDL checks: balance sheet credibility regulatory seriousness capital durability Pharma does not care about cannabis brands. They care about compliance, scale, and staying power. 6. “Why $4B if nothing has executed yet?” This is the crux. The DD does not claim $4B is deserved today. It claims: The downside is being priced as permanent The upside is being priced as zero A $4B valuation assumes: partial execution services revenue visibility SunStream drag removal no further balance sheet destruction That is a re-rating thesis, not a victory lap. Why This DD Still Matters Because it asks a different question than most cannabis debates: “What if SNDL is not trying to win cannabis, but trying to own the infrastructure cannabis eventually depends on?” You can disagree with that outcome. But dismissing it as “buzzwords” ignores: capital structure differences regulatory trajectory how pharma and infrastructure companies are actually built That’s why this isn’t pumping. It’s arguing the market may be pricing the wrong business model.

Trayeboujee

I'm simply trying to shed some light & educate people on SNDL and their fundamentals as they have been stomped on for so many years. I appreciate the concern, but this is not for pumping purposes but to just give some real insight on the companies path now/near and distant future

Orennji

1. So many lofty buzzwords! But forgot to mention that almost all the *existing* revenue comes from capital intensive alcohol retail, low margin cannabis grows and getting lucky selling shares on meme rallies. And there is no indication there is enough demand as a third party "service" provider to the industry, especially since many of the high margin services you list can be done better in-house or by more nimble specialized ancillary companies. 2. Tilray, Aurora and various other LPs already have fully owned GMP-certified facilities up and running for EU export. SNDL is far behind the race in this area. How can sndl become a leader in contract pharma services when they don't even have their own GMP license facility? If being "asset light" is just another word for being a middleman paying for someone else to do it, why is the middleman even necessary at all in this case? 2.5. Can you name one application of "AI" that is making a difference financially for SNDL, right now? 3. Modular grows are not a new idea. In fact, they were the main cultivation system used by the failed LP, Delta 9 Cannabis. There are no real efficiency gains from going this route, and if anything it creates costly redundancies in separate environmental controls and constant overheating. This is why no other crop is grown this way. And again, if other companies already have economies of scale in large greenhouse and outdoor facilities, what is SNDL's comparative advantage in this segment? 4. Where is the evidence of operational improvement in their investments? What have they improved? One example that is publicly listed is Jushi, which couldn't even break $1 million in operating revenue in recent quarters. Literally one of the worst MSOs that will probably be wiped out by the competition even with S3. This looks like a terrible result for a wannabe private equity investor. 5. Why would a pharma company want to partner with SNDL? You still haven't explained this. They have no GMP facilities of their own contract manufacturing, and they obviously have no experience with FDA approved drug trialing. 6. Why does SNDL deserve a $4 billion valuation if it hasn't executed anything, can't grow the existing business organically, and has done a terrible job at all the extracurricular activities they've attempted?

Trayeboujee

Most people are understandably skeptical because cannabis investors have been burned repeatedly. This isn’t about hype or a short-term price move. It’s about why SNDL is structurally different from Tilray, Canopy, and most legacy cannabis companies. The recent attention isn’t coming from pumping. It’s coming from mispricing. Most cannabis stocks are still being valued as asset-heavy growers with high debt, dilution risk, and dependence on legalization headlines. SNDL no longer fits that model. This DD matters because SNDL is transitioning into a services and infrastructure company. Contract manufacturing, global certifications, high-throughput modular production, structured credit through SunStream, and an asset-light balance sheet with cash and no debt put it in a different category entirely. Valuation follows business model. If you price SNDL like Tilray or Canopy it looks average. If you price it like a pharma-adjacent services platform it looks materially undervalued. This isn’t a pump because it avoids price hype and near-term catalysts. It lays out a 12 to 24 month roadmap, explains real risks, and focuses on why the market may be misclassifying the company. Even if you disagree with the thesis, understanding that distinction is useful for the community.

Trayeboujee

SNDL isn’t trying to own cannabis assets, it’s trying to own the control points. The real play isn’t vertical integration — it’s gatekeeping: certifications (GMP/FDA), compliant manufacturing capacity (pods), data, and capital. If you control the gates, you control the economics. Why pods matter: They standardize cannabis manufacturing like shipping containers did for global trade. Manufacturing becomes modular, compliant, and movable — real estate stops mattering, which strands MSOs stuck with owned facilities. SunStream isn’t just cleanup: It filters the industry. Weak operators fail, clean infrastructure survives, and SNDL redeploys it asset-light. Classic PE playbook at industry scale. Regulatory edge: Pharma-grade standards + research positioning signal “responsible operator” to regulators. That’s how you get grants, pilot programs, and early access. Big moat = data: AI-driven production tied to real retail demand (loyalty + SKU data) creates a learning system MSOs can’t replicate under debt. Bottom line: Even partial execution shifts SNDL from commodity cannabis to industry operating system. Upside asymmetric, downside capped.

MrSquigglyPub3s

SNDL

the_mammynun

If I wanted to invest in cash I'd invest in CRON. SNDL has solid retail assets in Canada (Nova, Inner Spirit Holdings), but they were both acquired via M&A. I prefer companies that prove they can grow organically. It's really important that management has an innate drive to network and innovate. SNDL's cash position is only proof that they can opportunitcally dilute shareholders to smitherines. SNDL's US assets don't interest me in the slightest. They got in too early. US entry needs to be extremely patient and thoughtful. There is plenty of time to enter what will be the biggest market worldwide. The winners won't be decided for another 10-20 years.

Trayeboujee

SNDL’s S3 strategy unfolds in three acts: 2025 validation, 2026 consolidation, and 2027 global pharma scaling.

King_Chron

People are overthinking SNDL. They’re **cash-flow positive**, **net cash**, running an **active buyback**, and the stock trades at roughly **\~0.5× EV**. That’s already cheap *before* you factor in optionality. Every buyback dollar at these prices is buying operating businesses + cash at a **50% discount**. That’s straight-up accretive, even with flat growth. Most cannabis names can’t do this — they’re levered, burning cash, or forced into dilution. SNDL isn’t. Rescheduling is the kicker. SNDL has **call options and strategic stakes** that get materially more valuable if regulations ease. The market is barely pricing that in. Downside is limited; upside is asymmetric. This isn’t a legalization lottery ticket. It’s a **balance-sheet + math** trade. Buybacks at \~0.5× EV tell you management thinks the stock is mispriced — and they’re putting cash behind it. That’s the story.

Trayeboujee

The infracture SNDL is building behind the scenes is astronomical, 2026 is going to be a great year IMO

Veganlightbody

SNDL is a junk stock and company. Avoid.

bourbonwarrior

On a global scale. Valens was a great acquisition by SNDL. Australian asset is significant, especially to process the CAN oversupply of biomass - low cost COGS, highest margin segments, all platforms - cannabis 2.0.

Trayeboujee

Great insight 👍 Let's also make it very clear to everyone else here in the weedstock forum SNDL isn’t trying to win cannabis, it’s trying to own the infrastructure that pharma must use once cannabis becomes medicine.

bourbonwarrior

The U.S. landscape faces a "Debt Tsunami" with approximately **$6 billion in maturities** coming due by 2026. SNDL's SunStream , which utilizes a Private Equity-style credit bidding model to acquire Tier-1 assets through foreclosure.    As these Dodo birds shed assets, SNDL/Sunstream and perhaps the Jupiter Fund cherry pick accretive elements vital to the value chain? Predators with 240M in unrestricted capital and the largest throughput in the industry - all platforms, all grades (HYTN has the DEL certification)

the_mammynun

SNDL is trash. They have never grown a single aspect of their business organically. They acquired several retailers + Valens via massive dilution on the backs of the earliest shareholders which is why the stock has plummeted since it's IPO. Their US operations (Parallel) are known to be indebted and were also acquired via dilution. Take a look at High Tide if you want to invest in a world class retailer and German cannabis wholesaler. They will play in the US too when the time is right, but their strategy will be financially sound unlike SNDL's.

bourbonwarrior

SNDL/Sunstream and perhaps Jupiter Fund could partner up and do what they do best - predator lend and secure prime, unfettered accretive assets in CAN-US-EU-AUS-Israel-UK-Germany and beyond. These firms might be going the way of the Dodo in 2026-27, by then SNDL will be a Pharma Grade juggernaut with the largest capacity, throughput, margins, etc reinforcing the "financial flywheel". Bash it, embrace it, I don't give a toss. Do your own research, trade accordingly.

King_Chron

wow a lot more people short SNDL than I thought in here or just want people to buy their heavy MSO bags so they dont want you looking anywhere else, **to all reading the baseless comments below that have no merit backing. take this as a real time to notice bad actors and educate yourself on the companies and pay more attention to the ones posting FUD in this sub**

ch0c0l8cake

SNDL and TLRY buyers - "This time is different" 😂🤣

Trayeboujee

While SNDL focuses on GMP, they can take advantage of CETA, which 90% of cannabis companies will not be eligible to do so and are only manufactuing at an agricultural level while SNDL is focusing on pharma grade products.

Ausdummer

Your subheading title says it all Irwin greaser, slink off with your SNDL hate

bourbonwarrior

Think of them more of a pharma grade highly efficient, margin optimizing contract manufacturer, the most throughput (on many levels) in the industry across multiple countries. No one in the industry can scale like them. Best part, no debt, 240M in unrestricted cash, predator market leader. Again, add in a JV, supply agreement, one more certification and dosing technology - Pharma contract manufacturer for the highest margin, high velocity throughput across all SNDL touchpoints plus partners/aligned friend-emies too

Trayeboujee

Sounds good! SNDL with their vertically integrated model is unique and a strategic play, decreasing their baseline cost significantly and aligning themselves more so as a distributor, hence their drive for pharma grade cannabis. SNDL invests heavily into invotated technology that will separate them from their competitors. What people really don't understand is that SNDL isn't worried about competing with companies such as Tilray or High tide, their looking more at the pharmaceutical companies which they will compete with, and now with S3 SNDL is quietly making their moves into this new open market.

bourbonwarrior

Yes, I can, but if ok with you, I'll send links via DM v on the board? With S3, SNDL unlocks a massive amount of value and not just Sunstream assets, which are truly impressive and spiffed up. Valens' IP is a force multiplier in a Pharma world.

Trayeboujee

Would you be able to send me the resources where you acquired your information so I could dive into some of these little deeper? SNDL is entering a complete new domain early on which they are aligned to dominate.

MidWestFineese

There are going to be some massive upcoming changes. CBSTF is going to get bought out by one of these companies.. or alcohol, tobacco, pharma. It's the only way in for these billion dollar companies.. is acquiring an already existing operator. That's why I am here as well as uplisting. I have been saying this for years. With a billion dollar backing, no 280e, there's going to be some massive upside. Wouldn't be surprised if SNDL or CRON acquires them. Cura is the sole operator I think will run on their own, they are too huge for anyone to pick them up. This sector will be great it's just a matter of how long yoy want to put up with the manipulation before you exit due to mental health or we get uplisted. These talks about acquiring these companies have already been in the works waiting on schedule 3.

heliumbox

GTIBF, CRON, maybe SNDL Only companies I'm fairly confident won't dilute for operations.

Love2Garden860

SNDL is one of the very few companies in the sector with zero debt and over $240 million in cash. In a high-interest-rate world, they are the "bank," not the borrower. Good luck to all!

Lebempe

I called it. https://www.reddit.com/r/SNDL/s/r80ZESGI6f

ch0c0l8cake

Let me ask something about weed stocks #Have any of you pot heads bought SNDL or TLRY branded weed? 😂🤣😂

Silberling36g

Nobody recognize the free call option on US-MSO... SNDL has a US footprint trough their Sunstream banking arm. After rescheduling they can convert in full equity.

DopeBook

SNDL calls?

Trayeboujee

He just gave you in depth DD with legitimate references & sources of inormation Clearly your not educating yourself enough in this space my friend and only following the noise. SNDL has been quietly making strategic moves in the background with a fantastic management team. Be careful who you lay in bed with because tomorrow everything could be gone

akaChadThundercock

I do have a small SNDL position I bought for shits and giggles and sold CCs on. I'll most likely get stuck with small gains if there's no rug pull this time lol. That said, I'd give SNDL a B rating as a company. Unlike many others, they are at basically 0 risk of going out of business. But they have some glaring issues I see. They basically have no organic growth. Everything they have, they bought with money from diluting their shareholders for a billion dollars the last sector run up. Most of their income is liquor retail. If someone thinks liquor is the product of the future, more power to you. That whole part of the business is fine, but basically should be ignored if weed is the thesis. Their grow operation has a very low ceiling. Since they run such a large retail operation, why would other retail companies buy from one of their biggest retail competitors when they can get similar product from other LPs? I see their vertical integration as a hindrance rather than a strength. Sunstream: SNDL got a bunch of cash burning assets for cheap. This goes back to their lack of organic growth. What have they done to show they can turn around a business in a highly competitive space? I'm not saying they can't, but SNDL supporters seem to think their dominance is guaranteed because they are now the owners of cash burning assets. All that negativity aside, I'm pretty confident they'll be around for the long haul. If nothing else, because they have a lot of money and aren't burning through it. This stock could definitely be multiple times it's current value in the next few years.

ging3r_gin3r

Amazingly thorough and robust. And happy to see some attention towards SNDL, the sleeping giant. Thank you for your DD here.

King_Chron

check my post into SNDL bull case - [https://www.reddit.com/r/weedstocks/comments/1ppcu59/sndl\_inc\_nasdaq\_sndl\_bull\_thesis\_capital/](https://www.reddit.com/r/weedstocks/comments/1ppcu59/sndl_inc_nasdaq_sndl_bull_thesis_capital/)

King_Chron

**SNDL Inc – Long-Term Bull Thesis (3–7 yrs) | NASDAQ: SNDL** * Market Cap: \~$536M | Cash: \~$178M | Debt: $0 | FCF 2025: \~$35–40M, projected $50M+ (2026) * Canadian ops: liquor (Ace Liquor, Liquor Depot, Wine & Beyond) + cannabis retail (Spiritleaf → Value Buds) + cannabis cultivation/production → stable cash flow * U.S. optionality via SunStream USA: \~$260M convertible debt → equity in FL, TX, MI, MA, NM → Top-5 North American MSO potential if federal legalization (Schedule III) occurs * 2025 revenue: $723M USD; Gross Margin \~26%; owner earnings \~$40–45M * Valuation: DCF & SOTP suggest $4–6/share vs current \~$2.10 → \~2–3x upside * Catalysts: U.S. federal rescheduling (removes 280E), SunStream conversions, Canadian consolidation, margin expansion via Indiva/private-label products * Capital Allocation: share buybacks $120–150M, Canadian tuck-ins $40–80M, U.S. roll-up via SunStream $150–300M **Bottom Line:** FCF-positive, cash-rich, undervalued Canadian retailer with embedded U.S. MSO optionality → asymmetric 3–7 yr upside.

BacKnightPictures

Thanks ChatGPT. I’ll take my chances with a company like SNDL that has zero debt, $250mm cash and is a leader in a burgeoning industry. Sure, the tangerine tyrant may not be able to reschedule via EO but at some point cannabis reform will happen. And to the other points here, there are no checks and balances to stop Dickless Donny so who’s to say an EO wouldn’t get the ball rolling on rescheduling? Also, nobody is expecting full scale “legalization” and rescheduling is key because it removes banking/institutional investment restrictions for public companies. Therefore cannabis companies would be provided access to loans, tax breaks and other financial vehicles previously prohibited under a S1 classification in the CSA

ging3r_gin3r

Hey mods can I get a flair that says “I’m not a giner” to pave the way to my glorious rise as a genitalia based roaring kitty of SNDL when this shit pops and I make tens of dollars?

ging3r_gin3r

SNDL bro

Kbarbs4421

SNDL feels like a laggard.to.me as well. Surprised they' still sitting well below their November high.

Trayeboujee

SNDL is the sleeping giant no one will expect.

Big_slice_of_cake

SNDL will run up too, I hope?

DopeBook

SNDL 🚀🚀

Ausdummer

$SNDL

Kbarbs4421

Yup, this is my rec as well. Also, SNDL. It's meme, but it has a solid balance sheet and significant MSO exposure via its Sunstream JV.

DopeBook

Bought some SNDL. Will see what happens with federal rescheduling. If it happens.

mc_snails

From what i remember from a old Hash investor deck, Hash sort of had SNDL's blessing in the conception of the company

The_Insider_Edge

Maybe SNDL would be a prime candidate for these maybe.

heliumbox

TLRY and CGC up bigly. CRON SNDL VFF HITI all hardly moving despite drastically better financials. Sector is so memey

the_mammynun

Raj is actually very wary (but open) to meeting Zach George, who has never personally reached out to him despite acquiring up to 10% of his stock. It was Raj himself who started these rumors (never pointing the finger at ZG himself, but it's obvious for those who follow closely). It's really not as elaborate as you think. SNDL buys into selling pressure slowly over time by continuously setting low bids, and then unloads rapidly into selling pressure. Even if you avoid dark pools it's entirely plausible. 

the_mammynun

I never said HITI grows cannabis, and the fact that they don't is one of their biggest strengths. They do however develop their own brands from other LP weed. Also, SNDL is primarily a retailer just like HITI. Yes they acquired Valens but the majority of their revenue comes from alcohol and cannabis retail.

the_mammynun

Zach George said publicly that it was to enhance SNDL's cash flows. I think there's more to it than that. HITI is SNDL's largest and most formidable competitor. While SNDL may own some production assets today (Valens), retail is in their DNA. They have already acquired certain alcohol retail brands, Nova cannabis stores (ValueBuds), and Inner Spirit Holdings (SpiritLeaf). It's no question that Canna Cabana is their largest threat especially because they both play in the discount segment.